-
公开(公告)号：US10022405B2
公开(公告)日：2018-07-17
申请号：US15358965
申请日：2016-11-22
Applicant: University Health Network
Inventor： Jeffrey A. Medin , Christopher J. Paige
IPC: A61K35/545
Abstract: Compositions and methods far delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
-
公开(公告)号：US20170056527A1
公开(公告)日：2017-03-02
申请号：US15211586
申请日：2016-07-15
Applicant: University Health Network
Inventor： Jeffrey A. Medin , Sean Devine
IPC: A61K48/00 , C07K14/705 , C12N15/86 , C12N9/12
CPC classification number: A61K48/0058 , A61K38/00 , C07H21/04 , C07K14/70503 , C07K2319/00 , C12N5/16 , C12N9/1229 , C12N15/63 , C12N15/85 , C12N15/86 , C12N15/861 , C12N15/8645 , C12N15/867 , C12N2740/15041 , C12N2740/15043 , C12N2740/16043 , C12N2840/203 , C12Y207/04009
Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.
Abstract translation: 本申请还涉及这些组合物在治疗疾病如移植物抗宿主病和癌症的方法中的用途。
-
公开(公告)号：US11597917B2
公开(公告)日：2023-03-07
申请号：US16619883
申请日：2018-06-06
Applicant: THE MEDICAL COLLEGE OF WISCONSIN, INC. , UNIVERSITY HEALTH NETWORK , WASHINGTON UNIVERSITY IN ST. LOUIS
Inventor： Jeffrey A. Medin , John F. Dipersio , Murtaza S. Nagree
IPC: C12N9/04 , A61P43/00 , A61K9/00 , A61K35/28 , C12N5/0789 , C12N7/00 , C12N9/40 , C12N9/24 , C12N9/80 , C12N15/86
Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
-
公开(公告)号：US10137205B2
公开(公告)日：2018-11-27
申请号：US15211586
申请日：2016-07-15
Applicant: University Health Network
Inventor： Jeffrey A. Medin , Sean Devine
IPC: C12N15/63 , C12N15/85 , C12N15/86 , C07H21/04 , A61K48/00 , C07K14/705 , C12N9/12 , C12N5/16 , C12N15/864 , C12N15/861 , C12N15/867 , A61K38/00
Abstract: The application relates to a composition comprising a stably integrating delivery vector, a modified mammalian thymidylate kinase (tmpk) that increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk, and a detection cassette fused to the tmpk. The application also relates to use of these compositions in methods of treatment of diseases, such as graft versus host disease and cancer.
-
公开(公告)号：US20200181582A1
公开(公告)日：2020-06-11
申请号：US16619883
申请日：2018-06-06
Applicant: THE MEDICAL COLLEGE OF WISCONSIN, INC , UNIVERSITY HEALTH NETWORK , WASHINGTON UNIVERSITY IN ST. LOUIS
Inventor： Jeffrey A. Medin , John F. Dipersio , Murtaza S. Nagree
IPC: C12N9/04 , C12N7/00 , C12N15/86 , C12N9/40 , C12N9/24 , C12N9/80 , A61K35/28 , C12N5/0789 , A61P43/00 , A61K9/00
Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
-
Patent Agency Ranking
公开(公告)号：US20140193449A1
公开(公告)日：2014-07-10
申请号：US14149911
申请日：2014-01-08
Applicant: University Health Network
Inventor： Jeffrey A. Medin , Andrea McCart , Severine Loisel-Meyer
CPC classification number: A61K39/0011 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2227/105 , A01K2267/0331 , A61K38/208 , A61K39/21 , A61K48/005 , A61K2039/5154 , A61K2039/5156 , A61K2039/5256 , A61K2039/53 , A61K2039/55522 , A61K2039/55538 , A61K2039/57 , A61K2039/575 , C07K14/5434 , C07K14/70503 , C07K2319/06 , C12N7/00 , C12N15/8509 , C12N15/86 , C12N2740/15021 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , C12N2740/16043
Abstract: Compositions and methods for delivering tumor associated antigens and immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer.
Abstract translation: 公开了用于递送肿瘤相关抗原和免疫调节分子以产生治疗效果的组合物和方法。 组合物和方法使用稳定整合的慢病毒递送系统。 该方法可用于治疗和预防性治疗诸如结肠癌的癌症。
-
公开(公告)号：US09439980B2
公开(公告)日：2016-09-13
申请号：US14037931
申请日：2013-09-26
Applicant: University Health Network
Inventor： Jeffrey A. Medin , Sean Devine
IPC: A61K48/00 , C12N15/00 , C12N15/63 , C12P21/04 , C07H21/04 , C07K14/705 , C12N9/12 , C12N15/86 , C12N15/85 , C12N5/16 , A61K38/00
CPC classification number: A61K48/0058 , A61K38/00 , C07H21/04 , C07K14/70503 , C07K2319/00 , C12N5/16 , C12N9/1229 , C12N15/63 , C12N15/85 , C12N15/86 , C12N15/861 , C12N15/8645 , C12N15/867 , C12N2740/15041 , C12N2740/15043 , C12N2740/16043 , C12N2840/203 , C12Y207/04009
Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.
-
公开(公告)号：US20160250309A1
公开(公告)日：2016-09-01
申请号：US15006923
申请日：2016-01-26
Applicant: University Health Network
Inventor： Jeffrey A. Medin , Andrea McCart , Severine Loisel
CPC classification number: A61K39/0011 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2227/105 , A01K2267/0331 , A61K38/208 , A61K39/21 , A61K48/005 , A61K2039/5154 , A61K2039/5156 , A61K2039/5256 , A61K2039/53 , A61K2039/55522 , A61K2039/55538 , A61K2039/57 , A61K2039/575 , C07K14/5434 , C07K14/70503 , C07K2319/06 , C12N7/00 , C12N15/8509 , C12N15/86 , C12N2740/15021 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , C12N2740/16043
Abstract: Compositions and methods for delivering tumor associated antigens and immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer.
Abstract translation: 公开了用于递送肿瘤相关抗原和免疫调节分子以产生治疗效果的组合物和方法。 组合物和方法使用稳定整合的慢病毒递送系统。 该方法可用于治疗和预防性治疗诸如结肠癌的癌症。
-
公开(公告)号：US10258653B2
公开(公告)日：2019-04-16
申请号：US14983672
申请日：2015-12-30
Applicant: University Health Network
Inventor： Jeffrey A. Medin , Christopher J. Paige
Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
-
10.发明申请VECTOR ENCODING THERAPEUTIC POLYPEPTIDE AND SAFETY ELEMENTS TO CLEAR TRANSDUCED CELLS 审中-公开编码治疗性多肽的载体和清除转导细胞的安全性元素公开(公告)号：US20160074533A1
公开(公告)日：2016-03-17
申请号：US14949639
申请日：2015-11-23
Applicant: University Health Network
Inventor： Jeffrey A. Medin
CPC classification number: A61K48/005 , A61K47/6825 , A61K47/6849 , A61K48/0083 , A61K2039/505 , C07K16/2866 , C07K2319/55 , C07K2319/74 , C12N9/1211 , C12N15/86 , C12N2740/15033 , C12N2740/15043 , C12N2740/17033 , C12N2740/17043 , C12N2750/14133 , C12N2750/14143 , C12N2799/027
Abstract: A composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) activator polynucleotide wherein the modified mammalian tmpk polynucleotide encodes a modified mammalian tmpk polypeptide that increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type mammalian tmpk polypeptide to a drug; and/or a targeting polynucleotide encoding a cell surface polypeptide that selectively binds a toxic binding agent. The disclosure also relates to use of these compositions in methods of treatment of diseases such as Fabry disease.
Abstract translation: 一种组合物，其包含：稳定整合递送载体; 修饰的哺乳动物胸苷酸激酶（tmpk）激活剂多核苷酸，其中修饰的哺乳动物tmpk多核苷酸编码修饰的哺乳动物tmpk多肽，其相对于由野生型哺乳动物tmpk多肽磷酸化为药物而使前药的磷酸化增加; 和/或编码选择性结合有毒结合剂的细胞表面多肽的靶向多核苷酸。 本公开还涉及这些组合物在治疗诸如法布里病的疾病的方法中的用途。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.018 seconds)
